TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01355159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo x 4 tablets will be taken daily by oral administration.
Study: NCT01534637
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01534637
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01640873
Drug: MK-8655
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
Study: NCT01640873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
Study: NCT00720226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill daily
Study: NCT02303314
Drug: Trigonella Foenum-graecum Seed Extract
Normalized name: Trigonella foenum-graecum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02303314
Drug: Drug: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01020799
Drug: AZD7268
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg, oral, twice daily (BID)
Study: NCT01020799
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules to match AZD7268
Study: NCT01020799
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match encapsulated escitalopram
Study: NCT00962988
Drug: Cost-Free Pharmacotherapy Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months.
Study: NCT00662259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, bid, p.o. for 28 +/- 2 days.
Study: NCT00792727
Drug: ketoprofen Patch
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 topical patches applied once daily for 28 days
Study: NCT03597867
Drug: Dicloftil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of drug 3 days prior to surgery
Study: NCT00568074
Drug: Glurenorm®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568074
Drug: Glucobay®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01602016
Drug: Folinic Acid and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
Study: NCT01949116
Drug: LDMTX
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly
Study: NCT01949116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly
Study: NCT03507413
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
Study: NCT00190242
Drug: group1
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix at 1440IU was administrated à weeks S0, S4 and S24
Study: NCT00190242
Drug: group2
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
Study: NCT03597867
Drug: Indom
Normalized name: Indomax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing of drug 3 days prior to surgery
Study: NCT02694874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the placebo control
Study: NCT01824901
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01148758
Drug: RO5323441
Approvals — FDA: no, EMA: no, PMDA: no
Description: cohorts receiving multiple doses iv
Study: NCT03130114
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
Study: NCT01764243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02397005
Drug: ZL-2102
Approvals — FDA: no, EMA: no, PMDA: no
Description: A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
Study: NCT02397005
Drug: Placebo matching ZL-2102
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03135652
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
Study: NCT02006537
Drug: GSK2256294
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
Study: NCT02593227
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion over 1 hour
Study: NCT02631876
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
Study: NCT00216645
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00489281
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
Study: NCT02714231
Drug: diclofenac sodium (cataflam)
Normalized name: diclofenac Oral Tablet [Cataflam]
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
Study: NCT00286819
Drug: the FEC75 and 95 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B
Study: NCT00536484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
Study: NCT01470612
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tablets, BID, for at least 12 months
Study: NCT01470612
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tablets, BID, for at least 12 months
Study: NCT01506908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: no active
Study: NCT02980250
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
Study: NCT02980250
Drug: normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
Study: NCT02605798
Drug: Elbanovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 400 mg sofosbuvir
Study: NCT00591331
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01197157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
Study: NCT01393457
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill
Study: NCT02197026
Drug: Hylan G-F 20
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02197026
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug treatment at the discretion of the investigator
Study: NCT04531657
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: influenza vaccine 0.5 ml intramuscularly during 2008-2009 season for measurement of A/Brisbane/59/2007(H1N1)-like, A/Brisbane/10/2007(H3N2)-like, and B/Florida/4/2006-like antigens
Study: NCT02283450
Drug: Qiliqiangxin Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04352465
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
Study: NCT04352465
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
Study: NCT04352465
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
Study: NCT00208117
Drug: Simvastatin (Zocor)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
Study: NCT00988936
Drug: [F-18]RGD-K5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with \[F-18\]RGD-K5
Study: NCT04147819
Drug: BAY2701439
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
Study: NCT03407118
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT03399318
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg load then 15mg/kg Q6 hours for the Aggressive Antipyretic Arm~Acetaminophen is also given to children in the placebo arm when they have a fever over 38.5 degrees Celsius during scheduled clinical assessments
Study: NCT03399318
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg Q6 hours for the Aggressive Antipyretic Arm
Study: NCT03399318
Drug: placebo for acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for acetaminophen for children in the Usual Care arm~For children in the Aggressive Antipyretic Arm, when they have a temperature over 38.5 degrees Celsius they are treated with a placebo
Study: NCT03399318
Drug: placebo for ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for ibuprofen
Study: NCT01484184
Drug: SPINALON (buspirone + levodopa + cardidopa)
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
Study: NCT03511170
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
Study: NCT04632706
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo to the Active IMP.
Study: NCT00551382
Drug: Muntelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets or granules; 4 mg once a day for 12 weeks
Study: NCT01246362
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
Study: NCT02212340
Drug: fresofol and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
Study: NCT02212340
Drug: desflurane and remifentanil
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
Study: NCT01093807
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily for 10 weeks
Study: NCT02689063
Drug: Maxigesic IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
Study: NCT02689063
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
Study: NCT02689063
Drug: IV Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
Study: NCT02689063
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
Study: NCT00350155
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02147249
Drug: antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
Study: NCT02172352
Drug: Ba 679 BR low dose
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02172352
Drug: Ba 679 BR middle dose
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02172352
Drug: Ba 679 BR high dose
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02172352
Drug: Placebo inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00257920
Drug: Zemplar® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mcg QOD
Study: NCT00257920
Drug: Hectorol® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 mcg QOD
Study: NCT02744131
Drug: Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate
Normalized name: cyproterone / ethinyl estradiol Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03043560
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill daily for 5 weeks
Study: NCT00773695
Drug: Aromatase Inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
Study: NCT00773695
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.
Study: NCT01117766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID dosing for 28 days
Study: NCT02429934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02554734
Drug: levodopa, carbidopa, ODM-104
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02554734
Drug: levodopa, carbidopa, entacapone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04248348
Drug: Low Molecular Weight Heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)
Study: NCT01564459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching compressed tablets, taken once daily at bedtime for 14 days.
Study: NCT00366041
Drug: Dermal substrate cellularised LG002 (10x10cm)
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: application depending on burn injury surface
Study: NCT03443518
Drug: Normal saline 0.9% IV infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
Study: NCT03443518
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
Study: NCT04637633
Drug: topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical preservative free artificial tears Q.I. D.
Study: NCT01613950
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
Study: NCT03380559
Drug: Injection, botulinum toxin + corticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)
Study: NCT03380559
Drug: Injection, placebo of toxin + corticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)
Study: NCT03380559
Drug: Injection, botulinum toxin + placebo corticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Intramuscular injection of botulinum toxin (Xeomin® 50 U) under ultrasound control~* Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)
Study: NCT02217631
Drug: Prednisolone low dose
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02217631
Drug: Prednisolone high dose
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02217631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04078438
Drug: treatment as usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
Study: NCT00794976
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00330564
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
Study: NCT00372112
Drug: GW642444
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW642444H
Study: NCT03119974
Drug: Tpo-RA discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (\> 2 months) complete response (platelets counts \> 100 x 109/L) period on Tpo-RA treatment.
Study: NCT02037165
Drug: Placebo to BI 1026706
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT02037165
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib hard capsule
Study: NCT02776514
Drug: Suplasyn1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02776514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01244061
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo twice daily
Study: NCT00940797
Drug: DMMET-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
Study: NCT00940797
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)